BioWorld MedTech

Jan. 11, 2016

Diabetic Foot Ulcer Market: Omnigraft approval seen as catalyst for Integra, DFU market

A new FDA approval is expected to be an important catalyst for Integra Lifesciences Corp. (Plainsboro, N.J.) and represents a step in the right direction for the broader diabetic foot ulcer (DFU) market. Read More

Inside the Beltway: Hatch, Wyden urge CMS to redo PAMA reporting mandates

Call Me Maybe: Cardiac variants fail to predict risk in prospective study

TAVR provides fertile market for firm: Vivasure Medical picks up CE mark for percutaneous vascular closure device

MDD's Company Stock Report

Opponents say not a wise move: Indian government urged to rethink health care price caps

Daily M&A: S&N completes acquisition of Blue Belt Holdings for $275M

Patent Watch: Biomarker Strategies gains key patents for core technology

Products

People in Places

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for July 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 16, 2025.

Atai Therapeutics discovers new 5-HT2A receptor partial agonists

BioWorld Science

Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...

PHD inhibitors reported in Akebia Therapeutics patent

BioWorld Science

Akebia Therapeutics Inc. has identified new derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate acting as prolyl 4-hydroxylase (PHD) inhibitors.

Woman in military clothing talking with psychologist

FDA wants more data for Otsuka’s sNDA in PTSD

BioWorld

The U.S. FDA is insisting that another study is needed to bolster the sNDA for Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. in treating adults with...